Answers are grounded in this paper and cite their sources.
Retrospective analysis identifies prognostic factors in patients with resectable PDAC, suggesting tailored postoperative strategies.
Background/Objectives While adjuvant S-1 is the standard of care for resected pancreatic ductal adenocarcinoma (PDAC) in Japan, the prognosis remains heterogeneous, with some patients facing poor outcomes. This study aimed to identify independent prognostic factors and develop a weighted scoring system for postoperative risk stratification after upfront surgery for resectable PDAC. Methods We retrospectively analyzed 173 patients who underwent upfront curative resection for resectable PDAC at a single institution (2015–2023). Among those receiving adjuvant chemotherapy, 97.2% were treated with S-1. Preoperative and pathological variables were evaluated using multivariable Cox regression to identify independent predictors of overall survival (OS), from which a weighted prognostic score was developed. Results The median OS was 53.5 months, with 3- and 5-year OS rates of 61.7% and 47.9%, respectively. Five independent prognostic factors were identified: CA19-9 ≥228 U/mL (HR 2.67), poorly differentiated histology (HR 2.60), low prognostic nutritional index (PNI <43.6; HR 2.12), tumor size >3 cm (HR 1.98), and R1 resection (HR 1.66). The model demonstrated robust predictive performance (optimism-corrected C-index: 0.743) and stratified patients into low-, intermediate-, and high-risk groups with 3-year OS rates of 92.2%, 58.3%, and 22.6%, respectively (p < 0.001). Conclusions Our weighted scoring system identifies high-risk patients who derive limited benefit from standard adjuvant S-1. Such individuals may be candidates for intensified postoperative strategies.
No takes yet. Share an insight, caveat, or question.
Mishima et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: